Over the past few weeks, research has begun on a new novel coronavirus, a vaccine commonly used in various countries to prevent tuberculosis (TB) around the world.
The vaccine called Bacillus chlamydia gonorrhoeae (BCG) is given to protect newborns and young children from TB.
Scientists in the United States now believe that the vaccine can prevent the effects of the corona virus, which can reduce hospital admissions and mortality.
The BCG vaccine is used to protect against TB, but in the United States it is also used to treat bladder cancer.
A recent study claimed that in countries where the vaccine is still widely used, coronavirus transmission and mortality rates are lower than in developed countries.
Texas A&M is now becoming the first university in the United States to test the vaccine on humans, with medical workers being part of it.
According to Jeffrey de Carrelo, a professor at the university’s science center, “this vaccine will not help protect people from the disease. In fact, this vaccine can be used to strengthen the immune system on a large scale.”
“It will make a big difference in the next two to three years until a specific vaccine for code 19 is developed,” he said.
Researchers were given 25 2.5 million last week to move their work forward as fast as possible, and a research video was released and the human trial will begin this week.
In the video, Professor Carillo says the vaccine will help people get treatment for code 19 immediately because the drug has already been approved by the FDA.
That is why research is being started directly from the fourth stage instead of the first 3 stages of vaccine testing.
The study will involve 1,800 medical workers and will be extended to other parts of the state, including Los Angeles and Boston.
So far, large-scale BC vaccine clinical trials have been announced in Australia, the Netherlands, Germany and the United Kingdom, with results expected in the next few weeks or months.
A study in late March claimed that people who had been vaccinated had some protection against code 19.
The study found that Code 19 cases and mortality rates are higher in countries where the vaccine is no longer used, such as the United States, Italy, Spain and France.
The vaccine is still widely used in Pakistan, India, China and many other countries.
The results of the study were published in medRxiv and the researchers claimed that in countries where the vaccine is being used, the death rate from code 19 is significantly lower.
The study found that countries where the vaccine was used late, such as Iran, where it was adopted in 1984, also have higher mortality rates, which reinforces the idea that the BCG should protect such elderly people. Who were given the vaccine as a child.
The researchers said that in countries using the vaccine, the number of certified cases of code 19 has also been reduced.
This vaccine contains a type of live and weakened TB germ, which develops immunity against the disease inside the body.
The study said that the widespread use of the BCG vaccine would reduce the number of people who spread code 19, while other measures would be possible to reduce its spread.
Researchers say that one of the reasons for the rapid spread of the virus in China is that during the Cultural Revolution of 1966 to 1986, TB prevention and treatment agencies were suspended and weakened, causing people to lose weight.